Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

A systematic survey of regional multi-taxon biodiversity: evaluating strategies and coverage.

Brunbjerg AK, Bruun HH, Brøndum L, Classen AT, Dalby L, Fog K, Frøslev TG, Goldberg I, Hansen AJ, Hansen MDD, Høye TT, Illum AA, Læssøe T, Newman GS, Skipper L, Søchting U, Ejrnæs R.

BMC Ecol. 2019 Oct 15;19(1):43. doi: 10.1186/s12898-019-0260-x.

2.

Philanthropy Profile: The Arthritis Foundation: Conquering Arthritis.

Skipper L.

N C Med J. 2017 Sep-Oct;78(5):341-343. doi: 10.18043/ncm.78.5.341. No abstract available.

3.

Hyperbaric oxygen for persistent post-concussive symptoms: long-term follow-up.

Skipper LD, Churchill S, Wilson SH, Deru K, Labutta RJ, Hart BB.

Undersea Hyperb Med. 2016 Aug-Sept;43(5):601-613.

PMID:
28768076
4.

Relationship of combat experiences and alcohol misuse among U.S. Special Operations Soldiers.

Skipper LD, Forsten RD, Kim EH, Wilk JD, Hoge CW.

Mil Med. 2014 Mar;179(3):301-8. doi: 10.7205/MILMED-D-13-00400.

PMID:
24594465
5.

Semantic memory: distinct neural representations for abstractness and valence.

Skipper LM, Olson IR.

Brain Lang. 2014 Mar;130:1-10. doi: 10.1016/j.bandl.2014.01.001. Epub 2014 Feb 19.

6.

Dissecting the uncinate fasciculus: disorders, controversies and a hypothesis.

Von Der Heide RJ, Skipper LM, Klobusicky E, Olson IR.

Brain. 2013 Jun;136(Pt 6):1692-707. doi: 10.1093/brain/awt094. Epub 2013 May 6. Review.

7.

Anterior temporal face patches: a meta-analysis and empirical study.

Von Der Heide RJ, Skipper LM, Olson IR.

Front Hum Neurosci. 2013 Feb 1;7:17. doi: 10.3389/fnhum.2013.00017. eCollection 2013.

8.

DbVar and DGVa: public archives for genomic structural variation.

Lappalainen I, Lopez J, Skipper L, Hefferon T, Spalding JD, Garner J, Chen C, Maguire M, Corbett M, Zhou G, Paschall J, Ananiev V, Flicek P, Church DM.

Nucleic Acids Res. 2013 Jan;41(Database issue):D936-41. doi: 10.1093/nar/gks1213. Epub 2012 Nov 27.

9.

Sensory and semantic category subdivisions within the anterior temporal lobes.

Skipper LM, Ross LA, Olson IR.

Neuropsychologia. 2011 Oct;49(12):3419-29. doi: 10.1016/j.neuropsychologia.2011.07.033. Epub 2011 Aug 22.

10.

Reporting the problem of chronic kidney disease in North Carolina.

Skipper L.

N C Med J. 2008 Sep-Oct;69(5):419. No abstract available.

PMID:
19006941
11.

Fine-mapping and candidate gene investigation within the PARK10 locus.

Haugarvoll K, Toft M, Skipper L, Heckman MG, Crook JE, Soto A, Ross OA, Hulihan MM, Kachergus JM, Sando SB, White LR, Lynch T, Gibson JM, Uitti RJ, Wszolek ZK, Aasly JO, Farrer MJ.

Eur J Hum Genet. 2009 Mar;17(3):336-43. doi: 10.1038/ejhg.2008.187. Epub 2008 Oct 15.

12.

The National Kidney Foundation of North Carolina.

Skipper L.

N C Med J. 2008 May-Jun;69(3):227. No abstract available.

PMID:
18751359
13.

Chronic kidney disease in North Carolina.

Alexander-Bratcher K, Plescia M, Skipper L, Silberman P, Holmes M.

N C Med J. 2008 May-Jun;69(3):197-204. No abstract available.

PMID:
18751352
14.

Validity of three accelerometers during treadmill walking and motor vehicle travel.

Maddocks M, Petrou A, Skipper L, Wilcock A.

Br J Sports Med. 2010 Jun;44(8):606-8. doi: 10.1136/bjsm.2008.051128. Epub 2008 Aug 13.

PMID:
18701531
15.

Genomic investigation of alpha-synuclein multiplication and parkinsonism.

Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, Adler CH, Larvor L, Chartier-Harlin MC, Nilsson C, Langston JW, Gwinn K, Hattori N, Farrer MJ.

Ann Neurol. 2008 Jun;63(6):743-50. doi: 10.1002/ana.21380.

16.

Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family.

Wider C, Skipper L, Solida A, Brown L, Farrer M, Dickson D, Wszolek ZK, Vingerhoets FJ.

Parkinsonism Relat Disord. 2008 Aug;14(6):465-70. doi: 10.1016/j.parkreldis.2007.11.013. Epub 2008 Mar 14.

PMID:
18342564
17.

Pathogenic mutations in Parkinson disease.

Tan EK, Skipper LM.

Hum Mutat. 2007 Jul;28(7):641-53. Review.

PMID:
17385668
18.

The use of advanced diffraction methods in the study of the structure of a bioactive calcia: silica sol-gel glass.

Newport RJ, Skipper LJ, Carta D, Pickup DM, Sowrey FE, Smith ME, Saravanapavan P, Hench LL.

J Mater Sci Mater Med. 2006 Nov;17(11):1003-10. Epub 2006 Nov 22.

PMID:
17122911
19.

LRRK2 G2019S founder haplotype in the Chinese population.

Tan EK, Skipper L, Tan L, Liu JJ.

Mov Disord. 2007 Jan;22(1):105-7.

PMID:
17083102
20.

The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence.

Tan EK, Zhao Y, Skipper L, Tan MG, Di Fonzo A, Sun L, Fook-Chong S, Tang S, Chua E, Yuen Y, Tan L, Pavanni R, Wong MC, Kolatkar P, Lu CS, Bonifati V, Liu JJ.

Hum Genet. 2007 Feb;120(6):857-63. Epub 2006 Sep 30.

PMID:
17019612
21.

Polymorphisms in candidate genes: implications for the current treatment of Parkinson's disease.

Skipper L, Liu JJ, Tan EK.

Expert Opin Pharmacother. 2006 May;7(7):849-55. Review.

PMID:
16634708
22.

Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.

Tan EK, Skipper L, Chua E, Wong MC, Pavanni R, Bonnard C, Kolatkar P, Liu JJ.

Mov Disord. 2006 Jul;21(7):997-1001.

PMID:
16602113
23.

Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease.

Skipper L, Li Y, Bonnard C, Pavanni R, Yih Y, Chua E, Sung WK, Tan L, Wong MC, Tan EK, Liu J.

Hum Mol Genet. 2005 Dec 1;14(23):3549-56. Epub 2005 Nov 3.

PMID:
16269443
24.

Analysis of LRRK2 functional domains in nondominant Parkinson disease.

Skipper L, Shen H, Chua E, Bonnard C, Kolatkar P, Tan LC, Jamora RD, Puvan K, Puong KY, Zhao Y, Pavanni R, Wong MC, Yuen Y, Farrer M, Liu JJ, Tan EK.

Neurology. 2005 Oct 25;65(8):1319-21.

PMID:
16247070
25.

Abeta42 is essential for parenchymal and vascular amyloid deposition in mice.

McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, DeLucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T.

Neuron. 2005 Jul 21;47(2):191-199. doi: 10.1016/j.neuron.2005.06.030.

26.

The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients.

Tan EK, Shen H, Tan LC, Farrer M, Yew K, Chua E, Jamora RD, Puvan K, Puong KY, Zhao Y, Pavanni R, Wong MC, Yih Y, Skipper L, Liu JJ.

Neurosci Lett. 2005 Aug 26;384(3):327-9.

PMID:
15955629
27.

A multinuclear solid state NMR study of the sol-gel formation of amorphous Nb2O5-SiO2 materials.

Drake KO, Carta D, Skipper LJ, Sowrey FE, Newport RJ, Smith ME.

Solid State Nucl Magn Reson. 2005 Jan;27(1-2):28-36.

PMID:
15589725
28.

alpha-Synuclein promoter confers susceptibility to Parkinson's disease.

Pals P, Lincoln S, Manning J, Heckman M, Skipper L, Hulihan M, Van den Broeck M, De Pooter T, Cras P, Crook J, Van Broeckhoven C, Farrer MJ.

Ann Neurol. 2004 Oct;56(4):591-5.

PMID:
15455394
29.

Identification of the human ubiquitin specific protease 31 (USP31) gene: structure, sequence and expression analysis.

Lockhart PJ, Hulihan M, Lincoln S, Hussey J, Skipper L, Bisceglio G, Wilkes K, Farrer MJ.

DNA Seq. 2004 Feb;15(1):9-14.

PMID:
15354349
30.

Linkage disequilibrium and association of MAPT H1 in Parkinson disease.

Skipper L, Wilkes K, Toft M, Baker M, Lincoln S, Hulihan M, Ross OA, Hutton M, Aasly J, Farrer M.

Am J Hum Genet. 2004 Oct;75(4):669-77. Epub 2004 Aug 3.

31.

Structural studies of bioactivity in sol-gel-derived glasses by X-ray spectroscopy.

Skipper LJ, Sowrey FE, Pickup DM, Fitzgerald V, Rashid R, Drake KO, Lin Z, Saravanapavan P, Hench LL, Smith ME, Newport RJ.

J Biomed Mater Res A. 2004 Aug 1;70(2):354-60.

PMID:
15227682
32.

Parkinson's disease in Ireland: clinical presentation and genetic heterogeneity in patients with parkin mutations.

Wiley J, Lynch T, Lincoln S, Skipper L, Hulihan M, Gosal D, Bisceglio G, Kachergus J, Hardy J, Farrer MJ.

Mov Disord. 2004 Jun;19(6):677-81.

PMID:
15197707
33.

Parkinson's genetics: molecular insights for the new millennium.

Skipper L, Farrer M.

Neurotoxicology. 2002 Oct;23(4-5):503-14. Review.

PMID:
12428722
34.

The tau H1 haplotype is associated with Parkinson's disease in the Norwegian population.

Farrer M, Skipper L, Berg M, Bisceglio G, Hanson M, Hardy J, Adam A, Gwinn-Hardy K, Aasly J.

Neurosci Lett. 2002 Apr 5;322(2):83-6.

PMID:
11958849
35.

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E.

Science. 2001 Aug 24;293(5534):1487-91.

36.

Pre-steady-state kinetic analysis of recombinant Arabidopsis NADH:nitrate reductase: rate-limiting processes in catalysis.

Skipper L, Campbell WH, Mertens JA, Lowe DJ.

J Biol Chem. 2001 Jul 20;276(29):26995-7002. Epub 2001 May 16.

37.

Incidence of liver disease in people with HFE mutations.

Willis G, Wimperis JZ, Lonsdale R, Fellows IW, Watson MA, Skipper LM, Jennings BA.

Gut. 2000 Mar;46(3):401-4.

38.

Strategic planning for material services in a multihospital system.

McGarrah K, Key JB, Etherton JL, Skipper L.

Hosp Mater Manage Q. 1990 Feb;11(3):1-11. No abstract available.

PMID:
10106351

Supplemental Content

Loading ...
Support Center